Abstract: Obeticholic acid is a novel selective FXR agonist that plays an important role in regulating bile acid metabolism, as well as glucose and lipid metabolism. It is a new drug candidate for primary biliary cirrhosis and nonalcoholic fatty liver disease. A series of studies have shown that obeticholic acid can alleviate the disease by inhibiting the progression of fibrosis and inhibiting the inflammatory process.

Key words: obeticholic ocid, FXR, primary biliary cholangitis, non-alcoholic steatohepatitis